Skip to content

Cytek Biosciences, Inc. CTKB Accrued excise taxes for share repurchase

Accrued excise taxes for share repurchase at other companies

LegalZoom.com, Inc. logo
LegalZoom.com, Inc.LZ
$356K
Sonos, Inc. logo
Sonos, Inc.SONO
$281K-57.9%
Energy Recovery logo
Energy RecoveryERII
$8.5K-91.2%
IPG Photonics logo
IPG PhotonicsIPGP
$0+100%
First Advantage Corporation logo
First Advantage CorporationFA
$195K
DoubleVerify Holdings logo
DoubleVerify HoldingsDV
$618K-15.6%

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept ctkb:AccruedExerciseTaxesForShareRepurchase.

The official record: Cytek Biosciences, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s accrued excise taxes for share repurchase.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s accrued excise taxes for share repurchase?
Cytek Biosciences, Inc. (CTKB) reported accrued excise taxes for share repurchase of $0 in Q4 2025.
What does accrued excise taxes for share repurchase mean?
Tracks the accrual of excise taxes specifically related to the company's share repurchase programs. It provides transparency into the tax-related costs associated with returning capital to shareholders through buybacks.